At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
brentuximab vedotindrug
Likely dose
brentuximab vedotin 1.8 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas
In Brief
A Phase 2 clinical trial evaluating brentuximab vedotin for Relapsed or Refractory EBV-and CD30-positive Lymphomas. Completed, enrolled 25 participants across 3 sites.
Detailed Summary
This is an open-label, non-randomized, multi-center, phase II trial of brentuximab vedotin to evaluate ORR primarily in patients with EBV- and CD30-positive lymphomas.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartMar 2016
Primary CompletionApr 2019
TodayJul 2026
First PostedMar 17, 2015
Enrollment StartMar 25, 2016
Primary CompletionApr 2, 2019
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 11.3 years ago
Interventions
brentuximab vedotindrug
Brentuximab vedotin administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg q 3 weeks.